ABSTRACT: WHO reported that the efficacy of artemisinin combination-based therapies (ACTs) has decreased around the Thai-Cambodian border. To maintain the efficacy and prolong the life span of ACTs, malarone (an atovaquone and proguanil combination) has been administered in Trat and Chanthaburi Provinces of Thailand since 2009. The mutations of codons 133, 258, 268, 272, 275, 280, 283, and 284 in the cytochrome b gene have been reported to be related to malarone resistance. This study investigates the susceptibility in vitro and mutations in the cytochrome b gene before and after the administration of malarone. Plasmodium falciparum infected blood samples obtained from malaria patients attending malaria clinics in these two provinces were included in this study. Fifteen parasite isolates were subjected to in vitro susceptibility tests against atovaquone. Their mean inhibitory concentrations ranged from 5 × 10 −9 -5 × 10 −10 M. The DNA sequences from 37 PCR samples revealed no mutations. Therefore the variation of drug susceptibility among these parasites may be unrelated to point mutations in the cytochrome b gene.
INTRODUCTION
Plasmodium falciparum, a parasite transmitted to humans by Anopheles mosquito, causes the most severe malaria. Unlike other malaria parasites, P. falciparum has the ability to rapidly transform itself into drug resistant population, especially those spread near the Thai-Cambodian border. This area has been known as an important centre of multidrug resistant development for several decades 1, 2 . To control this parasite, development and improvement of several drugs and drug regimens are needed 2 . A few years ago, the World Health Organization recommended the use of artemisinin-based combination therapy (ACTs) as a first-line malaria treatment in endemic areas where high incidence of drug resistance was established. Artemisinin and its derivatives rapidly reduced clinical symptoms and parasite burden. A 3-day artesunate-mefloquine (ARS-MQ) combination is currently being used as the first-line treatment against multidrug resistance malaria in this area. Unfortunately, recent reports from Cambodia showed that some parasites have a slightly reduced in vitro sensitivity to artesunate and a significant prolonged parasite clearance times [3] [4] [5] . This suggests that the parasite may have developed resistance against the ARS-MQ combination. In an attempt to delay the development of resistance, new antimalarial drugs are needed for the treatment.
Malarone is a drug of choice and it is a combination of atovaquone and proguanil. Atovaquone has been proposed as an inhibitor of a mitochondrial electron transport process, cytochrome bc1 complex, which collapses the mitochondrial membrane potential 6 . On the other hand, proguanil restrains the function of plasmodial dihydrofolate reductase (DHFR) enzyme and interferes with parasite DNA synthesis 7 . Malarone exhibits high efficacy for the treatment of drug resistant P. falciparum near the Thai-Myanmar border 8 . 20 were also reported to be associated with malarone resistance in vitro. The objective of this study was to investigate in vitro susceptibility against atovaquone and the mutations in cytochrome b genes before and after the administration of malarone in Thailand. These baseline data are important for monitoring of drug resistance situation in this area.
MATERIALS AND METHODS

Collection of parasites
P. falciparum samples were collected from Trat (TD, BR) and Chanthaburi (CH) provinces at Malaria Clinic during 1990-2011. Forty-one samples were cultured-adapted isolates and have been cryopreserved at Malaria Research Programme, Chulalongkorn University, Thailand. Twenty-two samples were collected using filter papers. The T9/94RC17 and K1CB1 are standard clones used as control clones, their MICs against other antimalarial drugs were previously determined and have been stable for many years.
In vitro drug sensitivity assay
Before the drug assay, the parasites were synchronized to ring stage using D-sorbitol method 21 . Drug susceptibility of malaria isolates against atovaquone was determined by minimum inhibitory concentration assay (MIC) 22, 23 . To perform drug susceptibility test, the synchronized parasites were adjusted to 0.3-0.5% parasitaemia with uninfected red blood cells. Then, 10 µl of parasites were added into the well of a 96 micro-well plate which contained 100 µl RPMI complete medium supplemented with antimalarial drugs at various concentrations; 0, 10 −10 , 5 × 10 −10 , 10 −9 , 5 × 10 −9 , and 7.5 × 10 −9 M, respectively. Each experiment was performed in triplicate. For comparison, T9/94RC17 and K1CB1 were included in all experiments to standardize the assay condition.
The RPMI medium (with or without drug/s) was changed daily. After 72 h, thin blood films stained with Giemsa were observed under light microscope. The minimum drug concentration at which the survived parasite cannot be detected was reported as the minimum inhibitory concentration (MIC) of the tested isolates or clones.
Genomic DNA extraction
The genomic DNA of P. falciparum was extracted by phenol-chloroform method as described by Snounou 24 . The DNA stock solutions were stored in a −20°C freezer throughout the experiment.
Polymerase Chain reaction
The cyt b gene was amplified by nested-PCR method 25 . One microlitre of diluted DNA template was added into the PCR reaction. The concentration of PCR reagents in the mixture were adjusted as followed: 1× Taq DNA polymerase buffer, 2 mM MgCl 2 , 0.25 mM dNTP, 0.25 mM of forward and reverse primers, and 2.5 unit Taq DNA polymerase in a 20 µl volume reaction. The temperature cycle was set as denaturation (95°C, 30 s), annealing (50°C, 30 s), and extension (72°C, 1 min) for 30 cycles using the Veriti 96-Well Thermal Cycler from Applied Biosystems. The forward and reverse primers were Plasmodium F (5 -GCCTAGACGTATTCCTGATTATCC AG-3 ), Plasmodium R (5 -CTCCCTATCATGTCTTGC TAACGGC-3 ), falciparum specific F (5 -GATGGAATA TGATTTGTTCTATTGGG-3 ), and falciparum specific R (5 -CCTTACGGTCTGATTTGTTCCGCTC-3 ).
The amplified products were determined by agarose gel electrophoresis 26 . Graphical information was captured by the Autochemi system (UVP, LLC).
DNA sequencing
The cyt b PCR products were purified and sequenced by Bio Basic Canada Inc. Sequences from both strands were aligned with BIOEDIT. The sequences of each isolates were deduced from the matched sequences in both strands. Finally, all sequences were compared and analysed for gene mutation.
RESULTS
From 41 P. falciparum samples, only 15 isolates were successfully revived. Most of the cultured isolates either became contaminated or died. Fourteen isolates were collected from Trat province during 1990-2008, before malarone was introduced as the first-line treatment. An isolate, TD559, was collected in 2010, one year after malarone was used. On the other hand, among the 22 samples collected by filter paper, 5 samples were collected from Trat TD3, TD498, TD500, TD506, TD530,  TD533, TD541, TD542, TD544, TD545,  TD547, TD550, TD554, TD556   BR17, BR26, BR102, TD373, TD371 2009-2011 Yes TD559 CH1, CH2, CH3, CH4, CH6, CH7, CH8, CH9, TD560, TD68, TD73, TD76, TD77, TD79,TD80, TD81,TD82
T9/94RC17 and K1CB1 were included as control clones. (Table 1 ). All fifteen parasite isolates, from Trat province, showed different levels of MIC. These isolates could be divided into three groups according to their MIC values, i.e., 5 × 10 −10 M (TD533, TD542, TD545, TD550, and TD554), 10 −9 M (TD530, TD541, TD544, and TD547), and 5 × 10 −9 M (TD3, TD498, TD500, TD506, TD556, and TD559) (Fig. 1) . 3D7 and K1CB1 clones gave the lowest (5 × 10 −10 M) and highest MIC (7.5 × 10 −9 M), respectively. In comparison, T9/94RC17 clone showed moderate MIC (5 × 10 −9 M) in this experiment. The PCR products of cyt b gene were detected as a 1254 bp fragment compared to the expected size at 1131 bp (Fig. 2) . No size polymorphism could be detected from the isolates and the control clones by agarose gel electrophoresis.
All PCR products were sequenced and analysed. The shortest readable sequences of the PCR products were from the 360th to the 902th which 
DISCUSSION
Two groups of P. falciparum samples had been analysed, those collected before and after the malarone had been introduced. These parasites showed different levels of MIC against atovaquone, even though atovaquone had never been used in Thailand. From the in vitro drug susceptibility assay against atovaquone, 3D7, T9/94RC17, K1CB1 exhibited variable MIC levels (Fig. 1) 20 have been proposed to be related to atovaquone resistance. In this experiment, the cyt b gene from 37 samples exhibited the same nucleotide sequences in all readable sequences in these positions. Similarly, no mutation at the codon 268 was detected among P. falciparum samples collected from Thai-Myanmar or Thai-Cambodian border 27, 28 . This suggested that the MIC value of the samples used in this experiment may not be related to previously reported mutations.
If previously proposed mutations are related to atovaquone resistance, these results suggest that atovaquone should still be effective against falciparum parasite in Thai-Cambodian border areas. Although none of tested isolates were categorized as high MIC against atovaquone similar to the K1CB1 clone, the misuse of atovaquone may help select these parasites and, finally, increase the tendency towards atovaquone resistance in the future.
